US2002098199A1PendingUtilityA1

Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences

41
Priority: Mar 10, 2000Filed: Mar 9, 2001Published: Jul 25, 2002
Est. expiryMar 10, 2020(expired)· nominal 20-yr term from priority
Inventors:Gary Van NestJoseph Eiden
A61P 31/14A61P 37/04A61P 43/00A61K 31/713A61P 1/16A61K 31/7088
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods are provided for the treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. A polynucleotide comprising an immunostimulatory sequence is administered to a individual who has been exposed to or infected by HBV and/or HCV. The polynucleotide is not administered with a HCV or HBV antigen. Administration of the polynucleotide results in amelioration of symptoms of HBV and/or HCV infection.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of reducing viremia in an individual infected with hepatitis B virus (HBV), comprising administering a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to said individual, wherein the ISS comprises the sequence 5′-C, G-3′, wherein an HBV antigen is not administered in conjunction with administration of said composition, and wherein said composition is administered in an amount sufficient to reduce HBV viremia.  
     
     
         2 . The method of  claim 1 , wherein the ISS comprises the sequence 5′-T, C, G-3′.  
     
     
         3 . The method of  claim 1 , wherein the ISS comprises the sequence 5′-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3′ or 5′-purine, purine, C, G, pyrimidine, pyrimidine, C, C-3′.  
     
     
         4 . The method of  claim 3 , wherein the ISS comprises a sequence selected from the group consisting of 5′-AACGTTCC-3′, 5′-AACGTTCG-3′, 5′-GACGTTCC-3′ and 5′-GACGTTCG-3′.  
     
     
         5 . The method of  claim 1 , wherein the ISS comprises the sequence 5′-TGACTGTGAACGTTCGAGATGA-3′ (SEQ ID NO:1).  
     
     
         6 . The method of  claim 1 , wherein the individual is a mammal.  
     
     
         7 . The method of  claim 1 , wherein administration is intravenous or subcutaneous.  
     
     
         8 . A method of reducing blood levels of a hepatitis virus antigen in an individual infected with hepatitis B virus (HBV), comprising administering a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to said individual, wherein the ISS comprises the sequence 5′-C, G-3′, wherein an HBV antigen is not administered in conjunction with administration of said composition, and wherein said composition is administered in an amount sufficient to reduce blood levels of a hepatitis virus antigen.  
     
     
         9 . The method of  claim 8 , wherein the ISS comprises the sequence 5′-T, C, G-3′.  
     
     
         10 . The method of  claim 8 , wherein the ISS comprises the sequence 5′-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3′ or 5′-purine, purine, C, G, pyrimidine, pyrimidine, C, C-3′.  
     
     
         11 . The method of  claim 10 , wherein the lSS comprises a sequence selected from the group consisting of 5′-AACGTTCC-3′, 5′-AACGTTCG-3′, 5′-GACGTTCC-3′ and 5′-GACGTTCG-3′.  
     
     
         12 . The method of  claim 8 , wherein the ISS comprises the sequence 5′-TGACTGTGAACGTTCGAGATGA-3′ (SEQ ID NO:1).  
     
     
         13 . The method of  claim 8 , wherein the individual is a mammal.  
     
     
         14 . The method of  claim 8 , wherein administration is intravenous or subcutaneous.  
     
     
         15 . The method of  claim 8 , wherein the hepatitis virus antigen is HBsAg.  
     
     
         16 . A kit for reducing viremia in an individual infected with or exposed to HBV, comprising a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5′-C, G-3′, wherein said kit does not comprise an HBV antigen; and wherein the kit comprises instructions for administration of said composition to an individual infected with or exposed to HBV to reduce viremia.  
     
     
         17 . The kit of  claim 16 , wherein the ISS comprises the sequence 5′-T, C, G-3′.  
     
     
         18 . The kit of  claim 16 , wherein the ISS comprises the sequence 5′-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3′ or 5′-purine, purine, C, G, pyrimidine, pyrimidine, C, C-3′.  
     
     
         19 . The kit of  claim 18 , wherein the ISS comprises the sequence 5′-AACGTTCG-3′.  
     
     
         20 . The kit of  claim 16 , wherein the ISS comprises the sequence 5′-TGACTGTGAACGTTCGAGATGA-3′ (SEQ ID NO:1).

Join the waitlist — get patent alerts

Track US2002098199A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.